Gradient Investments LLC Has $19.15 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Gradient Investments LLC raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 194,446 shares of the medical equipment provider’s stock after acquiring an additional 8,713 shares during the period. Gradient Investments LLC’s holdings in Zimmer Biomet were worth $19,153,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Brighton Jones LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $204,000. Public Sector Pension Investment Board lifted its stake in Zimmer Biomet by 11.4% in the first quarter. Public Sector Pension Investment Board now owns 27,284 shares of the medical equipment provider’s stock valued at $3,088,000 after buying an additional 2,789 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Zimmer Biomet by 13.3% in the first quarter. Russell Investments Group Ltd. now owns 82,897 shares of the medical equipment provider’s stock valued at $9,362,000 after buying an additional 9,758 shares during the period. Cresset Asset Management LLC increased its position in shares of Zimmer Biomet by 16.2% during the first quarter. Cresset Asset Management LLC now owns 43,219 shares of the medical equipment provider’s stock worth $4,902,000 after acquiring an additional 6,011 shares in the last quarter. Finally, Raymond James Financial Inc. raised its holdings in shares of Zimmer Biomet by 195.5% during the first quarter. Raymond James Financial Inc. now owns 594,097 shares of the medical equipment provider’s stock worth $67,240,000 after acquiring an additional 393,077 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Price Performance

Shares of ZBH opened at $90.90 on Wednesday. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. The company’s fifty day simple moving average is $95.35 and its 200 day simple moving average is $96.73. Zimmer Biomet Holdings, Inc. has a 1-year low of $85.33 and a 1-year high of $114.44. The company has a market cap of $18.01 billion, a price-to-earnings ratio of 22.50, a PEG ratio of 2.43 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the company posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. BTIG Research lowered their target price on Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Evercore ISI dropped their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 7th. Canaccord Genuity Group cut their target price on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a research note on Monday, November 10th. UBS Group decreased their price target on shares of Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a research note on Thursday, November 6th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $107.50.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.